Dapagliflozin in patients undergoing transcatheter aortic valve implantation (DapaTAVI)

Reported from ACC.25

Chiara De Biase interviews Sergio Raposeiras-Roubin about the results of the DapaTAVI trial which he presented during the ACC.25 in Chicago.

Among elderly patients with aortic stenosis undergoing TAVI and at high risk for heart failure, dapagliflozin was safe and reduced the incidence of all-cause death or worsening heart failure compared to standard care. Watch the interview to find out more.